Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Yoon Ho Ko, Myung Ah Lee, Yeong Seon Hong, Kyung Shik Lee, Hyun Jin Park, Ie Ryung Yoo, Yeon Sil Kim, Young Kyoon Kim, Keon Hyun Jo, Young Pil Wang, Kyo Young Lee, Jin Hyoung Kang
Korean J Intern Med. 2007;22(3):178-185. Published online September 30, 2007
BackgroundSecond-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedu..
|